Last reviewed · How we verify
Ocrelizumab Injection [Ocrevus]
Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation and demyelination.
Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation and demyelination. Used for Relapsing-remitting multiple sclerosis, Primary progressive multiple sclerosis.
At a glance
| Generic name | Ocrelizumab Injection [Ocrevus] |
|---|---|
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
| Drug class | CD20-targeting monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Immunology / Neurology |
| Phase | Phase 3 |
Mechanism of action
Ocrelizumab targets CD20, a surface antigen on B cells, leading to their selective depletion through antibody-dependent cellular cytotoxicity and direct induction of apoptosis. By reducing B cell populations, the drug decreases autoimmune attack on myelin and axons in the central nervous system. This mechanism reduces relapse rates and slows disability progression in multiple sclerosis.
Approved indications
- Relapsing-remitting multiple sclerosis
- Primary progressive multiple sclerosis
Common side effects
- Infusion-related reactions
- Upper respiratory tract infections
- Lower respiratory tract infections
- Headache
- Nasopharyngitis
- Immunosuppression / opportunistic infections